Molecular determinants of auto-immunity and immune adverse events in advanced cancer patients treated with immune checkpoint inhibitors.

Studying patient samples from 6 cancer trials of immunotherapy drugs, to examine side-effects related to the patients’ immune system.

Study Summary:

AUTO-CHECK uses biospecimens and data from trials of immune checkpoint inhibitors across 4 co-operative trials groups (ALTG, ANZGOG, ANZUP and COGNO). These trials span 5 tumour types: mesothelioma (DREAM); non-small cell lung (NIVORAD and ILLUMINATE), endometrial (PHAEDRA), renal cell (KEYPAD) and glioblastoma (NUTMEG).

Aims are to study:

1. Baseline molecular predictors of immune-related adverse events (IRAEs)
2. Identify common and rare genetic variants that segregate with IRAEs, and
3. Changes in peripheral blood lymphocytes (effector, memory and regulatory subsets), and the kinetics and distribution of CTLA4 and PD-1 expression in patients with or without IRAEs.

This translational research study was developed through the Genomics Cancer Clinical Trials Initiative GCCTI.

Supported By:

Cancer Australia project grant, Genomics Cancer Clinical Trials Initiative, ALTG, ANZGOG, ANZUP and COGNO



Registration ID:




Australian Lead Group:




Activation Date:

June 2017


Professor Matthew Cook (Australian National University, Canberra), and Dr Sonia Yip (CTC)


Study committee:

Matthew Cook (CIA), immunologist, NHMRC Centre for Research Excellence in Personalised Immunology

Sonia Yip

Martin Stockler

Desmond Yip, Canberra Hospital cohort

Anna Nowak, study chair DREAM mesothelioma ALTG

Paul Mitchell, study chair NIVORAD NSCLC ALTG

Yoland Antill, study chair PHAEDRA endometrial ANZGOG

Daniel Andrews

Chee Lee

Craig Gedye, study chair KEYPAD renal cell ANZUP

Mustafa Khasraw, study chair NUTMEG glioblastoma COGNO

Kristy Robledo, statistician

Michelle Parry, project officer

Carola Vinuesa

Matthew Links

Sayed Ali

Joost Lesterhuis